Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Recurrent Retinal Detachment
NCT02192970Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2015
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in rhegmatogenous retinal detachment (RRD), sponsored by University of Wisconsin–Madison. Started Jan 2015; status: completed.
02
Drugs
bevacizumab
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on NCT02192970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02192970.